Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides

Manan Pareeka Heart & Vascular Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA;b Department of Internal Medicine, Yale New Haven Hospital, Yale University School of Medicine, New Haven, CT, USA;c Department of Cardiology, North Zealand Hospital, Hillerød, DenmarkView further author information

R. Preston Masona Heart & Vascular Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA;d Elucida Research LLC, Beverly, MA, USAView further author information

Deepak L. Bhatta Heart & Vascular Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USACorrespondence[email protected]

https://orcid.org/0000-0002-1278-6245 View further author information

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (6)

Meleeka Akbarpour, Divya Devineni, Yufan Gong & Nathan D. Wong. (2023) Dyslipidemia Treatment and Lipid Control in US Adults with Diabetes by Sociodemographic and Cardiovascular Risk Groups in the NIH Precision Medicine Initiative All of Us Research Program. Journal of Clinical Medicine 12:4, pages 1668.
Crossref

Bansi Sutariya, Diana M Montenegro, Michael Chukwu, Paghunda Ehsan, Rawia N Aburumman, Shivani Ishwarya Muthanna, Swathi Radhakrishnan Menon, Vruti Vithani & Sai Sri Penumetcha. (2022) Emphasis on Icosapent Ethyl for Cardiovascular Risk Reduction: A Systematic Review. Cureus.
Crossref

Prakriti Gaba, Deepak L. Bhatt, Ph. Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Steven B. Ketchum, Rebecca A. Juliano, Lixia Jiao, Ralph T. DoyleJr.Jr., Craig Granowitz, Jean-Claude Tardif, Robert P. Giugliano, Fabrice M.A.C. Martens, C. Michael Gibson & Christie M. Ballantyne. (2022) Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction. Journal of the American College of Cardiology 79:17, pages 1660-1671.
Crossref

Benjamin E. Peterson, Deepak L. Bhatt, Ph. Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Steven B. Ketchum, Rebecca A. Juliano, Lixia Jiao, Ralph T. DoyleJr.Jr., Craig Granowitz, C. Michael Gibson, Duane Pinto, Robert P. Giugliano, Matthew J. Budoff, Jean‐Claude Tardif, Subodh Verma & Christie M. Ballantyne. (2022) Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI. Journal of the American Heart Association 11:6.
Crossref

Ines Drenjančević & Jan Pitha. (2022) Omega-3 Polyunsaturated Fatty Acids—Vascular and Cardiac Effects on the Cellular and Molecular Level (Narrative Review). International Journal of Molecular Sciences 23:4, pages 2104.
Crossref

Deepak L. Bhatt. (2022) Substantial Impact of Eicosapentaenoic Acid on Cardiovascular Outcomes in the REDUCE-IT Trial. CardioMetabolic Syndrome Journal 2:1, pages 22.
Crossref

Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides

Articles from other publishers (6)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides

Citations (6)

Articles from other publishers (6)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date